Skip to main content
Vineet Laboratories Limited logo

Vineet Laboratories Limited — Investor Relations & Filings

Ticker · VINEETLAB ISIN · INE505Y01010 LEI · 98450053FEE2D64C6147 BSE.NS Manufacturing
Open in API
Filings indexed 272 across all filing types
Latest filing 2026-05-15 Capital/Financing Update
Country IN India
Listing BSE.NS VINEETLAB

About Vineet Laboratories Limited

http://vineetlabs.co.in/

Vineet Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and API intermediates. The company focuses on producing high-quality chemical compounds through advanced research and development, catering to diverse therapeutic segments including anti-retroviral, anti-diabetic, and anti-hypertensive treatments. Its core operations involve the synthesis of complex molecules and fine chemicals, supported by manufacturing facilities that adhere to rigorous quality management systems. Vineet Laboratories provides custom synthesis and contract manufacturing services, positioning itself as a technical partner for global healthcare organizations. The company emphasizes process optimization and cost-effective production to deliver reliable chemical solutions for large-scale pharmaceutical applications.

Recent filings

Filing Released Lang Actions
Monitoring Agency Report
Capital/Financing Update Classification · 80% confidence The document is a detailed Monitoring Agency Report issued by Crisil Ratings for the quarter ended March 31, 2026, on the utilization of proceeds from a Rights Issue. It is a regulatory disclosure to stock exchanges regarding how the funds raised through the Rights Issue have been deployed. This is not an annual or interim financial report, nor an audit report, director change notice, earnings release, or dividend announcement. Instead, it is an update related to the company’s capital‐raising activity and the subsequent use of those funds, fitting the "Capital/Financing Update (CAP)" category.
2026-05-15 English
Please find the attached Monitoring Agency Report issued by Crisil Rating Limited for the quarter ended March 31, 2026
Audit Report / Information Classification · 88% confidence The document is a Monitoring Agency Report issued by Crisil Ratings for the quarter ended March 31, 2026 under SEBI ICDR Regulations. It contains detailed tables on proceeds utilization, issuer details, and agency declarations, and is submitted to stock exchanges as a regulatory compliance report. This is not an earnings release, interim financial report, or simple announcement, but a standalone regulatory monitoring report akin to an audit/compliance report. Hence it falls under Audit Report / Information (Code: AR).
2026-05-15 English
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
Regulatory Filings
2026-04-29 English
Structural Digital Database
Regulatory Filings
2026-04-21 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-21 English
Trading Window
Regulatory Filings
2026-03-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.